William Burman and colleagues review the barriers to involving children in studies of new tuberculosis treatments and recommend strategies for overcoming these barriers

A. Sarah Walker

Andrew A Vernon

Badri

Barnes

Bolton-Moore

Chapuis

Chow

Diana M Gibb

Donald

Fairall

Gandhi

Gibb

Gortmaker

Havens

Hesseling

Lindtjorn

Lounis

Marais

Mark F Cotton

Matsumoto

Meibohm

Mitnick

Nelson

Nikonenko

Palella

Peter R Donald

Radilla-Chavez

Ragno

Rosenthal

Schaaf

Stover

Tanguis

Vargas

William J Burman

PLoS Medicine

English

PubMed

A Sarah Walker

Directory of Open Access Journals

Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens.

The Essay SectionThe original publication is available at http://www.plosmedicine.orgGlobal tuberculosis control is threatened by dramatic increases in HIV-related tuberculosis and by the emergence of multidrug-resistant strains. Highly lethal outbreaks of extensively drugresistant tuberculosis among HIVinfected persons in South Africa demonstrate the public health emergency that results when these two forces converge in the same setting.  Fortunately, at this time of great need, tuberculosis drug development has been roused from its decades-long slumber. New ways of using existing drugs and the development of new
drug classes hold great promise for the treatment of both drug-susceptible and drug-resistant tuberculosis.  Children are a critical part of the
global tuberculosis pandemic, with an estimated 900,000 cases and 100,000 deaths per year.Publishers' Versio

Burman, William J.

Cotton, Mark F.

Gibb, Diana M.

Walker, A. Sarah

Vernon, Andrew A.

Donald, Peter R.

Stellenbosch University SUNScholar Repository

Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens

We are on the threshold of revolutionary improvements in the treatment of tuberculosis. Within five to ten years, it is likely that highly effective three-month regimens will be available to treat both active and latent drug-susceptible tuberculosis. New drug classes that have the potential to dramatically improve the treatment of multidrug-resistant tuberculosis are entering clinical trials. Children have the same right as adults to benefit from research with these new treatments. By making a deliberate choice to avoid the path of least resistance, we can ensure that both adults and children benefit from these advances in tuberculosis treatment

Burman, WJ

Cotton, MF

Gibb, DM

Walker, Ann

Vernon, AA

Donald, PR

Oxford University Research Archive

Walker, AS

UCL Discovery

Crossref

Ensuring the Involvement of Children in the Evaluation of New Tuberculosis Treatment Regimens

ORA - Oxford University Research Archive

A refined symptombased approach to diagnose pulmonary tuberculosis in children.

A smallmolecule nitroimidazopyran drug candidate for the treatment of tuberculosis.

Antimycobacterial pyrroles: synthesis, anti-Mycobacterium tuberculosis activity and QSAR studies.

children receiving antiretroviral therapy at primary health care facilities in Zambia.

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.

Community-based therapy for multidrug-resistant tuberculosis in

Cost-effectiveness of highly active antiretroviral therapy in South Africa.

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.

Diagnosis of sputumscarce HIV-associated pulmonary tuberculosis in

Diagnostic and management challenges for childhood tuberculosis in the era of HIV.

Drug therapy of experimental tuberculosis (TB): Improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.

Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.

Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: Randomised controlled trial.

Effectiveness of antiretroviral treatment in a South African program: A cohort study.

Extensively drugresistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.

Factors predicting non-completion of tuberculosis treatment among HIV-infected patients in

Food and Drug Administration Amendments Act of

Global epidemiology of childhood tuberculosis.

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.

Increasing antiretroviral drug access for children with HIV infection.

Isoniazid pharmacokinetics in children treated for respiratory tuberculosis.

La cuerda dulce—A tolerability and acceptability study of a novel approach to specimen collection for diagnosis of paediatric pulmonary tuberculosis.

OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

Outcome of HIV-infected children with culture-confirmed tuberculosis. Arch Dis Child.

Population pharmacokinetic studies in pediatrics: Issues in design and analysis.

Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.

Results of directly observed treatment for tuberculosis in Ensenada, Mexico: Not all DOTS programs are created equally.

Sputum induction for the diagnosis of pulmonary tuberculosis in infants and young children in an urban setting in South Africa.

Streptomycin treatment of pulmonary tuberculosis.

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications.

TBTC Study 26: Weekly RFP/INH for 3 mo. vs. daily INH for 9 mo. for the treatment of LTBI. Available: http://www.clinicaltrials.gov/ct2/ show/NCT00023452?term=tuberculosis%2C+ri fapentine&rank=5.

The assessment of new antituberculosis drugs for a paediatric indication.

The bacteriologic yield in children with intrathoracic tuberculosis.

The EU Paediatric Regulation. Available: http://www. emea.europa.eu/htms/human/paediatrics/ regulation.htm.

The natural history of childhood intra-thoracic tuberculosis: A critical review of literature from the prechemotherapy era.

The outcome of tuberculosis treatment at a rural hospital in southern Ethiopia.

The spectrum of disease in children treated for tuberculosis in a highly endemic area.

Tuberculosis research and development: A critical analysis of funding trends, 2005-2006. Treatment Action Group. Available: http://www.aidsinfonyc.org/tag/ tbhiv/tbrandd/2007tbranddreport.pdf.

World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology.

World Health Organization

http://scholar.sun.ac.za/bitstream/10019.1/21891/1/burman_ensuring_2006.pdf

Ensuring the Involvement of Children in the Evaluation of New Tuberculosis Treatment Regimens

Abstract

Similar works

Full text

Available Versions